Cancer therapy with a parvovirus combined with bevacizumab
AssigneesDeutsches Krebsforschungszentrum, Ruprecht-Karis-Universität Heidelberg
InventorsKarsten Geletneky, Jean Rommelaere, Wolfgang Wick, Antje Wick, Michael Dahm
Life of this patent
Estimating the term…
Abstract
Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.
Claims9
A method for treating a brain tumor comprising administering a pharmaceutical combination containing (a) a parvovirus in combination with (b) bevacizumab, wherein said parvovirus is H-1 (H-1PV).
A kit comprising a first container, a second container and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing parvovirus H-1, the second container comprises at least one dose of a pharmaceutical composition comprising bevacizumab, and the package insert comprises instructions for treating an individual having a brain tumor using the pharmaceutical composition(s).
Dependencies are inferred from the claim text.